The frequency of ipsilateral second tumors after breast-conserving surgery for DCIS - A population-based analysis

被引:53
作者
Warren, JL
Weaver, DL
Bocklage, T
Key, CR
Platz, CE
Cronin, KA
Ballard-Barbash, R
Willey, SC
Harlan, LC
机构
[1] NCI, Div Canc Control & Populat Sci, Hlth Serv & Econ Branch, Appl Res Program, Bethesda, MD 20892 USA
[2] Univ Vermont, Coll Med, Dept Pathol, Burlington, VT 05405 USA
[3] Univ New Mexico, Hlth Sci Ctr, Dept Pathol, Albuquerque, NM 87131 USA
[4] Univ New Mexico, Hlth Sci Ctr, New Mexico Tumor Registry, Albuquerque, NM 87131 USA
[5] Univ Iowa, Coll Med, Dept Pathol, Iowa City, IA 52242 USA
[6] Georgetown Univ Hosp, Betty Lou Ourisman Breast Hlth Ctr, Dept Surg, Washington, DC 20007 USA
关键词
ductal carcinoma in-situ; breast carcinoma; population-based study; outcomes study; breast-conserving surgery;
D O I
10.1002/cncr.21406
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND. The diagnosis of ductal carcinoma in situ (DCIS) is increasing, although to the authors' knowledge there is no consensus regarding optimal treatment. This analysis of women treated with breast-conserving surgery (BCS) evaluated the impact of radiation therapy (RT) in patient outcomes. METHODS. The current study included a population-based sample of 1103 women residing in selected Surveillance, Epidemiology, and End Results (SEER) registries who were diagnosed with DCIS between 1991-1992. Data were obtained from the registry, physician follow-up, and pathology reports. Physicians were contacted in 1999 to determine whether the patient had developed a second event in the ipsilateral breast. For second events, pathology reports were reviewed to determine the presence of in situ or invasive disease. Registry data through 2001 were used to assess death rates and cause of death. Cox proportional hazards and logistic regression models were used to evaluate the rates of second events and breast carcinoma deaths between women treated with and without RT. RESULTS. Over an average of 91 months, 13.2% of women developed a second event. Rates of second events were 11% for women treated with BCS and RT compared with 15% for women treated with BCS only (adjusted hazards ratio, 0.64; 95% confidence interval, 0.44-0.92). Women receiving RT were significantly less likely to develop invasive breast carcinoma in the ipsilateral breast (adjusted odds ratio, 0.40). By 200 1, the rate of death from breast carcinoma was 2.7%; in the group of women treated with BCS only compared with 0.8% in the group of women treated with BCS with RT. CONCLUSIONS. Among a population-based cohort, RT was found to significantly reduce the risk of second events in the ipsilateral breast, particularly invasive tumors, although not to the extent reported in clinical trials.
引用
收藏
页码:1840 / 1848
页数:9
相关论文
共 30 条
[1]  
[Anonymous], 1997, AJCC CANC STAGING MA
[2]   Effects of patient selection on the applicability of results from a randomised clinical trial (EORTC 10853) investigating breast-conserving therapy for DOS [J].
Bijker, N ;
Peterse, JL ;
Fentiman, IS ;
Julien, JP ;
Hart, AAM ;
Avril, A ;
Cataliotti, L ;
Rutgers, EJT .
BRITISH JOURNAL OF CANCER, 2002, 87 (06) :615-620
[3]  
Bocklage T, 2001, MODERN PATHOL, V14, p23A
[4]  
Boyages J, 1999, CANCER, V85, P616, DOI 10.1002/(SICI)1097-0142(19990201)85:3<616::AID-CNCR12>3.3.CO
[5]  
2-Z
[6]   A NEW METHOD OF CLASSIFYING PROGNOSTIC CO-MORBIDITY IN LONGITUDINAL-STUDIES - DEVELOPMENT AND VALIDATION [J].
CHARLSON, ME ;
POMPEI, P ;
ALES, KL ;
MACKENZIE, CR .
JOURNAL OF CHRONIC DISEASES, 1987, 40 (05) :373-383
[7]  
CUNNINGHAM J, 1992, SEER PROGRAM CODE MA, P64
[8]   ADAPTING A CLINICAL COMORBIDITY INDEX FOR USE WITH ICD-9-CM ADMINISTRATIVE DATABASES [J].
DEYO, RA ;
CHERKIN, DC ;
CIOL, MA .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1992, 45 (06) :613-619
[9]   Mortality among women with ductal carcinoma in situ of the breast in the population-based surveillance, epidemiology and end results program [J].
Ernster, VL ;
Barclay, J ;
Kerlikowske, K ;
Wilkie, H ;
Ballard-Barbash, R .
ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (07) :953-958
[10]  
Ernster VL, 2002, JNCI-J NATL CANCER I, V94, P1546